Have you been paying attention to shares of Corcept Therapeutics (CORT) ? Shares have been on the move with the stock up 16.2% over the past month. The stock hit a new 52-week high of $62.98 in the previous session. Corcept Therapeutics has gained 23.6% since the start of the year compared to the -2.1% move for the Zacks Medical sector and the -7.9% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't ...

Core Insights - Chuck Jones has extensive experience in equity analysis and investment management, with a focus on technology and life sciences sectors [1] - He has successfully developed strategies for wealth management targeting technology executives and private equity partners [1] - Jones has a strong track record of outperforming industry benchmarks through financial modeling and direct engagement with company leadership [1] Group 1: Career Background - Chuck Jones has a total of twelve years as an equity analyst and sixteen years in various roles at IBM [1] - He has held significant positions at Northern Trust and Atlantic Trust Private Wealth Management, focusing on technology holdings [1] - His early career included a lead analyst role for Internet Security Software at Smith Barney, where he authored comprehensive industry reports [1] Group 2: Skills and Achievements - Jones utilized extensive financial modeling and industry contacts to achieve superior performance over six consecutive years [1] - He has been recognized with multiple sales awards during his tenure at IBM, including a President's award [1] - His educational background includes a B.S. in Industrial Engineering from Stanford University and a Postgraduate Diploma in Economics from the University of Sussex [1]

Core Insights - Corcept Therapeutics announced data from the phase II DAZALS study evaluating dazucorilant for treating amyotrophic lateral sclerosis (ALS) [1] - The study did not meet its primary endpoint, leading to a decline in Corcept's shares in pre-market trading [2] - Year-to-date, Corcept's shares have increased by 85%, contrasting with a 4.6% decline in the industry [3] Study Details - The DAZALS study was a double-blind, placebo-controlled trial assessing two doses of dazucorilant (150 mg and 300 mg) [1] - Patients treated with dazucorilant experienced significantly more gastrointestinal upset compared to the placebo group [4] - An open-label, long-term extension study will continue, with overall survival data expected in March next year [5] Regulatory and Pipeline Updates - The FDA has granted Fast Track Designation to dazucorilant for ALS treatment [7] - Corcept's lead pipeline candidate, relacorilant, is in phase III of the GRACE study for Cushing's syndrome [8] - An NDA for relacorilant in Cushing's syndrome is anticipated to be submitted shortly [10] Additional Studies - Relacorilant is also being evaluated in combination with other drugs for various cancer indications, including a phase III study for platinum-resistant ovarian cancer [11]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

A month has gone by since the last earnings report for Corcept Therapeutics (CORT) . Shares have added about 19.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Corcept Beats Q3 Earnings & Sales Estimates, ...

Welcome to my profile!My name is Vincent. I have over three years of experience as a tech-oriented buy-side analyst at a major bank, where I co-managed U.S. equity portfolios with over $700M in assets under management. I’ve worked across both large-cap and small-cap stocks, gaining a deep understanding of financial markets. Fascinated by innovation and its potential, my goal is not only to identify tomorrow's future leaders but also to share and discuss these insights with you.I believe every investor shoul ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Corcept Therapeutics (CORT) closed the last trading session at $54.31, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $74.90 indicates a 37.9% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.03. While the lowest estimate of $67 indicates a 23.4% increase from the current price level, the most optimistic analyst ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...